You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The age of enlightenment in melanoma immunotherapy
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, August 2018
|
| DOI | 10.1186/s40425-018-0397-8 |
| Pubmed ID | |
| Authors |
Mark R. Albertini |
| Abstract |
An updated survival analysis by Callahan et al. published in the February 1, 2018 issue of the Journal of Clinical Oncology reported a 3-year overall survival (OS) rate of 63% for 94 patients with previously treated or untreated advanced melanoma who received ipilimumab and nivolumab as concurrent therapy in a phase 1 dose escalation study CA209-004 (n = 53) or in an expansion cohort with the dose and schedule of concurrent ipilimumab and nivolumab now approved for patients with unresectable or metastatic melanoma (n = 41). While this 3-year OS rate of 63% in patients with measurable, unresectable stage III or IV melanoma is an impressive accomplishment that compares very favorably with historical metastatic melanoma survival rates, findings from larger phase 3 studies are needed to determine whether combination immunotherapy significantly improves survival more than single agent immunotherapy with PD-1 blockade. This Commentary discusses the transition from the dark ages to the age of enlightenment in melanoma immunotherapy and provides a roadmap for a better tomorrow for patients with metastatic melanoma. |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 10 | 77% |
| Italy | 2 | 15% |
| Unknown | 1 | 8% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 38% |
| Practitioners (doctors, other healthcare professionals) | 4 | 31% |
| Scientists | 3 | 23% |
| Science communicators (journalists, bloggers, editors) | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 62 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 16% |
| Student > Master | 8 | 13% |
| Other | 7 | 11% |
| Student > Ph. D. Student | 7 | 11% |
| Student > Bachelor | 5 | 8% |
| Other | 8 | 13% |
| Unknown | 17 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 27% |
| Biochemistry, Genetics and Molecular Biology | 8 | 13% |
| Agricultural and Biological Sciences | 5 | 8% |
| Immunology and Microbiology | 4 | 6% |
| Chemistry | 3 | 5% |
| Other | 7 | 11% |
| Unknown | 18 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 November 2020.
All research outputs
#2,031,457
of 25,385,509 outputs
Outputs from Journal for Immunotherapy of Cancer
#536
of 3,422 outputs
Outputs of similar age
#40,955
of 342,357 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#10
of 36 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,422 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,357 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.